Psilocybin and Alcohol Addiction: The Hopkins Trials Explained
In August 2022, the journal JAMA Psychiatry published results from a randomised controlled trial that sent shockwaves through the addiction medicine community. Researchers at Johns Hopkins and NYU found that psilocybin-assisted therapy produced an 83% reduction in heavy drinking days among participants with alcohol use disorder — compared to 51% in the active placebo group. Eight months after treatment, 48% of psilocybin participants had stopped drinking entirely.
These numbers are extraordinary by the standards of addiction medicine, where even the best available treatments (naltrexone, acamprosate, intensive CBT) produce abstinence rates of 20–30% at one year.
How the Trial Worked
The trial enrolled 93 adults with alcohol use disorder who were motivated to reduce or stop drinking. Participants were randomised to receive either two psilocybin sessions or two sessions with an active placebo (diphenhydramine, an antihistamine). All participants also received twelve weeks of motivational enhancement therapy.
Psilocybin sessions were conducted in a comfortable, supervised environment with trained therapists present. Participants wore eyeshades and listened to a curated music playlist, a protocol designed to facilitate inward-focused, emotionally meaningful experiences.
Why Psilocybin Works for Alcohol Addiction
Alcohol use disorder involves multiple overlapping mechanisms: physical dependence, conditioned cravings triggered by environmental cues, and the psychological factors (depression, anxiety, trauma) that drive drinking. Psilocybin appears to address the last two simultaneously.
By disrupting the Default Mode Network — the self-referential thought loop that sustains addictive narratives ("I need a drink to cope," "I can't change") — psilocybin creates a window of psychological flexibility in which new patterns of thinking and behaviour can be established. The mystical-type experiences it produces are associated with increased motivation to change, reduced craving, and a fundamental shift in how participants relate to alcohol.
Neuroimaging studies show that psilocybin reduces activity in the nucleus accumbens (the brain's craving centre) and promotes neuroplasticity in the prefrontal cortex — the region responsible for impulse control and long-term decision-making.
The Role of Psychotherapy
The psychotherapy component is not incidental. Participants who reported the most intense mystical-type experiences during psilocybin sessions showed the greatest reductions in drinking — but only when those experiences were processed and integrated in therapy. Psilocybin appears to open a window; therapy determines what is built in that window.
What This Means for Treatment
If these results are replicated in larger trials — and several Phase 3 trials are now underway — psilocybin-assisted therapy could represent the most significant advance in addiction medicine in decades. The prospect of achieving lasting recovery with two to three sessions, rather than years of ongoing medication and therapy, would transform the economics and accessibility of addiction treatment.
Frequently Asked Questions
How effective is psilocybin for alcohol addiction?
The Johns Hopkins/NYU trial found an 83% reduction in heavy drinking days and 48% abstinence at eight months — dramatically better than current standard treatments.
How many psilocybin sessions are needed for alcohol addiction?
The Hopkins trial used two sessions, eight weeks apart. Both sessions contributed to outcomes, with the second session often producing the deepest and most transformative experiences.
Can psilocybin help with cravings for alcohol?
Yes. Neuroimaging studies show psilocybin reduces activity in the brain's craving circuits, and participants in trials consistently report reduced desire to drink that persists long after the sessions end.